MaxCyte (MXCT) announced the completion of an internal operational review, initiated earlier this year following the appointment of Maher Masoud as president and CEO. This “bottom-up” review focused on optimizing new product development, manufacturing, commercial execution, and capital allocation to enhance efficiency and align resources with strategic priorities. As part of an effort to streamline operations, the company made adjustments to its workforce which affected 21 positions, reflecting approximately 15% of its personnel globally, including both directly employed individuals and those engaged through third-party employer-of-record arrangements. Anticipated cost savings in 2025 as a result of this action are expected to be about $5.8M. Following this adjustment, combined with other personnel decisions made throughout the year, MaxCyte expects to end the year with 116 employees, compared with 143 employees at the end of 2023.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MXCT:
- MaxCyte Streamlines Workforce and Boosts Revenue Outlook
- MaxCyte Expands Stock Capital Amid Cell Therapy Growth
- MaxCyte’s Voting Rights Shift with BlackRock Acquisition
- MaxCyte Sees Shift in BlackRock’s Shareholding
- MaxCyte Weighs Delisting from AIM to Prioritize Nasdaq: Potential Benefits and Risks Ahead
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
